[{"id":"556b24f4-a540-4e32-bed4-b81cc50ddf9a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00526045","created_at":"2021-01-18T01:54:04.948Z","updated_at":"2024-07-02T16:36:37.192Z","phase":"Phase 1/2","brief_title":"Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients","source_id_and_acronym":"NCT00526045","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 overexpression • HER-2 amplification","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e luminespib (AUY922)"],"overall_status":"Completed","enrollment":" Enrollment 117","initiation":"Initiation: 07/01/2007","start_date":" 07/01/2007","primary_txt":" Primary completion: 04/01/2012","primary_completion_date":" 04/01/2012","study_txt":" Completion: 04/01/2012","study_completion_date":" 04/01/2012","last_update_posted":"2020-12-17"},{"id":"eb98d175-5a34-46f6-845c-f629ab6302c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02276027","created_at":"2021-01-18T10:42:42.037Z","updated_at":"2024-07-02T16:36:37.310Z","phase":"Phase 2","brief_title":"A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02276027","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • Mektovi (binimetinib) • Zykadia (ceritinib) • Tabrecta (capmatinib) • luminespib (AUY922)"],"overall_status":"Completed","enrollment":" Enrollment 66","initiation":"Initiation: 01/20/2015","start_date":" 01/20/2015","primary_txt":" Primary completion: 10/15/2019","primary_completion_date":" 10/15/2019","study_txt":" Completion: 10/15/2019","study_completion_date":" 10/15/2019","last_update_posted":"2020-12-16"},{"id":"dd89f6a6-8c72-4405-a4f8-ba95ababd5a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01613950","created_at":"2021-01-18T06:54:48.090Z","updated_at":"2024-07-02T16:36:37.607Z","phase":"Phase 1","brief_title":"PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer","source_id_and_acronym":"NCT01613950","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • PIK3CA","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • PIK3CA mutation","tags":["HER-2 • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • luminespib (AUY922)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 03/01/2014","primary_completion_date":" 03/01/2014","study_txt":" Completion: 03/01/2014","study_completion_date":" 03/01/2014","last_update_posted":"2020-12-09"},{"id":"fe2ea4e8-cbb7-4bab-8f68-0897e6024013","acronym":"","url":"https://clinicaltrials.gov/study/NCT01271920","created_at":"2021-01-18T05:08:38.739Z","updated_at":"2024-07-02T16:36:37.636Z","phase":"Phase 1/2","brief_title":"Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab","source_id_and_acronym":"NCT01271920","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • luminespib (AUY922)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 10/01/2013","primary_completion_date":" 10/01/2013","study_txt":" Completion: 10/01/2013","study_completion_date":" 10/01/2013","last_update_posted":"2020-12-08"},{"id":"cfc79c3c-37ef-4a18-bf47-b2fdd946273f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01784640","created_at":"2021-01-18T07:52:45.292Z","updated_at":"2025-02-25T15:40:37.769Z","phase":"Phase 1","brief_title":"Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT01784640","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" EGFR • KRAS • ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["EGFR • KRAS • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pemetrexed • luminespib (AUY922)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 01/31/2014","start_date":" 01/31/2014","primary_txt":" Primary completion: 10/11/2018","primary_completion_date":" 10/11/2018","study_txt":" Completion: 10/11/2018","study_completion_date":" 10/11/2018","last_update_posted":"2020-09-03"},{"id":"20b63c84-5fbb-4f76-a357-de7569544623","acronym":"","url":"https://clinicaltrials.gov/study/NCT01922583","created_at":"2021-01-18T08:40:42.278Z","updated_at":"2024-07-02T16:37:08.883Z","phase":"Phase 2","brief_title":"AUY922 in Patient With Stage IV NSCLC","source_id_and_acronym":"NCT01922583","lead_sponsor":"National Taiwan University Hospital","biomarkers":" EGFR • HER-2 • BRAF • ALK • RET • ROS1 • EML4 • KIF5B • SLC34A2","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF mutation • BRAF V600 • HER-2 mutation • ALK positive • EGFR T790M • RET fusion • EGFR exon 20 insertion • ALK rearrangement • HER-2 exon 20 insertion • ALK fusion • RET mutation • KIF5B-RET fusion • ALK translocation • EGFR exon 20 mutation • BRAF D594G • BRAF G469A • EGFR A767_V769dup • HER-2 YVMA • TFG-ALK fusion • BRAF exon 15 mutation","tags":["EGFR • HER-2 • BRAF • ALK • RET • ROS1 • EML4 • KIF5B • SLC34A2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF mutation • BRAF V600 • HER-2 mutation • ALK positive • EGFR T790M • RET fusion • EGFR exon 20 insertion • ALK rearrangement • HER-2 exon 20 insertion • ALK fusion • RET mutation • KIF5B-RET fusion • ALK translocation • EGFR exon 20 mutation • BRAF D594G • BRAF G469A • EGFR A767_V769dup • HER-2 YVMA • TFG-ALK fusion • BRAF exon 15 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e luminespib (AUY922)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 02/01/2017","primary_completion_date":" 02/01/2017","study_txt":" Completion: 02/01/2017","study_completion_date":" 02/01/2017","last_update_posted":"2018-07-18"},{"id":"8b190744-a340-4375-8523-8b2ee76f81c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01854034","created_at":"2021-01-18T08:16:50.512Z","updated_at":"2024-07-02T16:37:11.624Z","phase":"Phase 2","brief_title":"Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR","source_id_and_acronym":"NCT01854034","lead_sponsor":"Massachusetts General Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e luminespib (AUY922)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 07/01/2013","start_date":" 07/01/2013","primary_txt":" Primary completion: 03/01/2017","primary_completion_date":" 03/01/2017","study_txt":" Completion: 03/01/2017","study_completion_date":" 03/01/2017","last_update_posted":"2018-04-10"},{"id":"2f2e68f9-1654-40ba-af06-8aa7ed876dca","acronym":"","url":"https://clinicaltrials.gov/study/NCT01752400","created_at":"2021-01-18T07:41:27.772Z","updated_at":"2024-07-02T16:37:12.733Z","phase":"Phase 2","brief_title":"AUY922 for Advanced ALK-positive NSCLC","source_id_and_acronym":"NCT01752400","lead_sponsor":"Massachusetts General Hospital","biomarkers":" KRAS • ALK","pipe":" | ","alterations":" KRAS mutation • ALK translocation","tags":["KRAS • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e luminespib (AUY922)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 01/01/2013","start_date":" 01/01/2013","primary_txt":" Primary completion: 06/01/2017","primary_completion_date":" 06/01/2017","study_txt":" Completion: 11/01/2017","study_completion_date":" 11/01/2017","last_update_posted":"2018-03-29"},{"id":"fd33c77e-5c23-4001-8195-7121e96973e6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01361945","created_at":"2021-01-18T05:34:20.652Z","updated_at":"2024-07-02T16:37:22.700Z","phase":"Phase 1/2","brief_title":"AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer","source_id_and_acronym":"NCT01361945","lead_sponsor":"Texas Tech University Health Sciences Center, El Paso","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib • letrozole • luminespib (AUY922)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/01/2011","start_date":" 07/01/2011","primary_txt":" Primary completion: 08/01/2012","primary_completion_date":" 08/01/2012","study_txt":" Completion: 08/01/2012","study_completion_date":" 08/01/2012","last_update_posted":"2017-05-09"}]